Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27:454-460
Published online before print December 28, 2006, doi: 10.1161/01.ATV.0000256471.22437.88
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
27/3/454    most recent
01.ATV.0000256471.22437.88v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tollefsen, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tollefsen, D. M.
Related Collections
Right arrow Regulation of Hemostasis and Thrombosis: Murine Models
Right arrowRelated Article
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27:454.)
© 2007 American Heart Association, Inc.


ATVB In Focus

Heparin Cofactor II Modulates the Response to Vascular Injury

Douglas M. Tollefsen

From Division of Hematology, Department of Medicine, Washington University Medical School, St. Louis, Mo.

Correspondence to Douglas M. Tollefsen, Division of Hematology, Campus Box 8125, Washington University Medical School, 660 South Euclid Avenue, St. Louis, MO 63110. E-mail tollefsen{at}im.wustl.edu

Series Editor: David T. Eitzman

Heparin cofactor II (HCII) has several biochemical properties that distinguish it from other serpins: (1) it specifically inhibits thrombin; (2) the mechanism of inhibition involves binding of an acidic domain in HCII to thrombin exosite I; and (3) the rate of inhibition increases dramatically in the presence of dermatan sulfate molecules having specific structures. Human studies suggest that high plasma HCII levels are protective against in-stent restenosis and atherosclerosis. Studies with HCII knockout mice directly support the hypothesis that HCII interacts with dermatan sulfate in the arterial wall after endothelial injury and thereby exerts an antithrombotic effect. In addition, HCII deficiency appears to promote neointima formation and atherogenesis in mice. These results suggest that HCII plays a unique and important role in vascular homeostasis.


Key Words: heparin cofactor II • thrombin • thrombosis • atherogenesis • restenosis


Related Article:

Regulation of Hemostasis and Thrombosis: Insights from Murine Models
Daniel T. Eitzman
Arterioscler Thromb Vasc Biol 2007 27: 453. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
Mol. Cell. Biol.Home page
M. Maccarana, S. Kalamajski, M. Kongsgaard, S. P. Magnusson, A. Oldberg, and A. Malmstrom
Dermatan Sulfate Epimerase 1-Deficient Mice Have Reduced Content and Changed Distribution of Iduronic Acids in Dermatan Sulfate and an Altered Collagen Structure in Skin
Mol. Cell. Biol., October 15, 2009; 29(20): 5517 - 5528.
[Abstract] [Full Text] [PDF]


Home page
J. Exp. Biol.Home page
A. Mulenga, R. Khumthong, and M. A. Blandon
Molecular and expression analysis of a family of the Amblyomma americanum tick Lospins
J. Exp. Biol., September 15, 2007; 210(18): 3188 - 3198.
[Abstract] [Full Text] [PDF]